Skip to content

Combine and Conquer: Minimizing the Impact of Toxicity Associated with Novel Immunotherapy-Angiogenesis Inhibitor Combinations 
Endometrial Carcinoma Tweetorial *Post-Test*

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.
1.Where are you in your career?(Required.)
2.Which I/O + 🎯tx combo is FDA approved for treatment of advanced or metastatic endometrial carcinoma?

nivo= nivolumab
dostar= dostarlimab-gxly
pembro = pembrolizumab(Required.)
3.What is the most common grade 3 or higher toxicity associated w/ the combination of pembro & lenva in pts w/ endometrial cancer?(Required.)
4.During tx w/ pembro-lenva, a pt develops grade 3 HTN requiring reduction in lenva. Starting dose of lenva was 20mg. Which dose is recommended for lenva now?(Required.)
5.During treatment w pembro & lenva, pt develops frequent, loose, watery stools. How could you quickly determine which drug is causing the diarrhea?(Required.)
EVALUATION FORM
6.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
EXPRESS awareness of AEs associated with anti-angiogenic therapy and how they differ from immune-mediated AEs
DIFFERENTIATE etiology and presentation of overlapping toxicities with AA/IO combination therapy
SELECT optimal strategies to prevent and manage common AEs experienced by patients treated with AA/IO combination therapy
7.Please indicate the extent of your agreement with the following statements:
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective
The educational resources and/or handouts provided to me at the educational activity are useful to my practice
8.Overall, was this activity fair, balanced and free from commercial bias?
9.If no, please explain:
10.Of the patients you will see in the next month, about how many will benefit from the information you learned today?
11.Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):
12.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
13.For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*(Required.)
14.I certify that I have participated in the continuing education activity entitled, "Combine and Conquer: Minimizing the Impact of Toxicity Associated with Novel Immunotherapy-Angiogenesis Inhibitor Combinations | Endometrial Carcinoma Tweetorial" and claim 0.25 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Privacy & Cookie Notice